Antisoma and Raylo sign major manufacturing deal for AS1411
Cancer drug developer Antisoma plc announced that it has signed an agreement with Raylo Chemicals of Edmonton, Alberta, Canada, for the manufacture of AS1411 (formerly AGRO100). Quantities produced will be amongst the largest to date for any aptamer drug, and sufficient to support multiple clinical trials. Antisoma is planning a programme of trials to evaluate thoroughly the efficacy of AS1411, building on promising signs of anti-cancer activity seen in a phase I study conducted at the Brown Cancer Center in Louisville, Kentucky, USA.
Raylo, a subsidiary of Degussa, has considerable expertise in the production of aptamers and other oligonucleotide drugs, having been involved in the manufacture of Pfizer and Eyetech's Macugen, the first aptamer drug to gain FDA approval.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.